摘要
目的快速评估艾普拉唑肠溶片治疗十二指肠溃疡的有效性、安全性和经济性,为临床和决策者提供参考。方法计算机检索PubMed、Embase、the Cochrane Library、中国知网(CNKI)、万方数据库和国内外卫生技术评估(HTA)机构官方网站,纳入艾普拉唑对比其他药物治疗十二指肠溃疡的HTA报告、系统评价/Meta分析和药物经济学研究,采用定性描述的方法汇总纳入研究的结论。结果共纳入10篇文献,其中系统评价/Meta分析5篇、经济学研究6篇(有1篇系统评价/Meta分析同时也进行了经济性研究)。在治疗十二指肠溃疡的有效性方面,艾普拉唑(10 mg·d^-1)与其他PPIs方案的疗效相当,且艾普拉唑(10 mg·d^-1)和艾普拉唑(5 mg·d^-1)的疗效并无统计学差异;与H2受体拮抗剂相比,艾普拉唑(10 mg·d^-1)治疗十二指肠溃疡的疗效显著优于雷尼替丁和法莫替丁。安全性方面,艾普拉唑(10 mg·d^-1)与其他PPIs或H2受体拮抗剂方案的不良反应发生率无统计学差异。在治疗十二指肠溃疡的经济性方面,艾普拉唑(10 mg·d^-1)相较于艾司奥美拉唑(40 mg·d^-1)不具有经济性,而艾普拉唑(5 mg·d^-1)比雷贝拉唑(10 mg·d^-1)更具经济性。结论艾普拉唑肠溶片在治疗十二指肠溃疡方面安全有效,不劣于其他PPIs,且相比雷贝拉唑具有一定的经济性。因艾普拉唑(10 mg·d^-1)和艾普拉唑(5 mg·d^-1)疗效相当,临床上可考虑采用低剂量方案以进一步提高其安全性和经济性。同时,有必要进一步开展低剂量艾普拉唑治疗十二指肠溃疡的临床研究,以完善相关证据。
OBJECTIVE To rapidly evaluate the efficacy,safety and economical efficiency of ilaprazole enteric-coated tablets in the treatment of duodenal ulcer,so as to provide evidence-based evidence for clinical rational drug use.METHODS PubMed,Embase,the Cochrane Library,CNKI,WanFang database and health technology assessment(HTA)organization websites were searched systematically.HTA reports,systematic reviews/Meta-analysis and pharmacoeconomic studies comparing ilaprazole with other drugs for duodenal ulcer treatment were included.Qualitative and descriptive analysis were performed on the included studies.RESULTS A total of 10 literatures were included,including five systematic reviews/Meta-analysis and six pharmacoeconomic research(one systematic reviews/Meta-analysis also carried out pharmacoeconomic research).The efficacy of ilaprazole(10 mg·d^-1)was comparable to other PPIs regimens in the treatment of duodenal ulcer,and there was no statistically significant difference in the efficacy of ilaprazole(10 mg·d^-1)and ilaprazole(5 mg·d^-1).Compared with H2 receptor antagonists,ilaprazole(10 mg·d^-1)was significantly better than ranitidine and famotidine in the treatment of duodenal ulcer.In terms of safety,there was no statistical difference in the incidence of adverse reactions between ilaprazole(10 mg·d^-1)and other PPIs or H2 receptor antagonists.In terms of the economics of treating duodenal ulcer,ilaprazole(10 mg·d^-1)was not economical compared to esmeprazole(40 mg·d^-1),while ilaprazole(5 mg·d^-1)was more economical than rabeprazole(10 mg·d^-1).CONCLUSION Ilaprazole enteric-coated tablets are safe and effective in the treatment of duodenal ulcer,not inferior to other PPIs,and have economic advantages compared with rabeprazole.Because ilaprazole(10 mg·d^-1)and ilaprazole(5 mg·d^-1)have comparable efficacy,a low-dose regimen could be considered clinically to further improve its safety and cost performance.At the same time,it is necessary to further carry out clinical and pharmacoeconomic studies of low-dose ilaprazole in the treatment of duodenal ulcer to improve the relevant evidence.
作者
李婷
赵紫楠
胡欣
裴艺芳
李可欣
杨蕾
谭玲
LI Ting;ZHAO Zi-nan;HU Xin;PEI Yi-fang;LI Ke-xin;YANG Lei;TAN Ling(Department of Pharmacy,Beijing Hospital,Beijing 100730,China;Clinical Trial Center,Beijing Hospital,Beijing 100730,China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2020年第13期1111-1116,共6页
Chinese Pharmaceutical Journal
基金
“国家重大新药创制”科技重大专项资助项目(2017zx09101001002002)。
